Social Determinants of Health

Maternal Mortality Review Committees (MMRCs) are multi-disciplinary committees that convene at the state or local level to comprehensively review deaths of women during or within a year of pregnancy. This document summarizes substance use disorder findings in a recent review of MMRC data in 14 states.

This report aims to address the treatment opportunities for pregnant and postpartum (or parenting) women (PPW) with substance use disorder (SUD) by describing opportunities to integrate obstetricians and gynecologists (OB/GYN) and SUD care as well as barriers to integrated care delivery.

This research report from NIDA discusses sex and gender influences in substance use, highlighting the unique needs of women when addressing substance use. disorder treatment

The following checklist intends to support health care teams in providing evidence-based recommendations for treating pregnant and postpartum patients with OUD. The checklist is divided into five sections, sequenced by timing of presentation to care.

This Guide to meant to help health care teams recognize, rethink and remediate the stigma and bias of words commonly used in caring for people with the chronic disease of substance use disorder:

This resource offers background information and tips for providers on how to use person-first language and on which terms to avoid using to reduce stigma and negative bias when discussing addiction or substance use disorder with pregnant women and mothers.

MCPAP for Moms provides obstetricians, midwives, and PCPs with psychiatric consultation for behavioral health concerns and questions around medications when pregnant or breastfeeding. MCPAP for Moms also supports connections with community-based services and support groups.

This document summarizes the discussion from the meeting of clinicians and researchers who are knowledgeable about screening for fentanyl and other drugs, primarily in health care settings. The focus of the meeting was to understand clinician/researcher perspectives about clinical fentanyl testing and distribution of fentanyl test strips (FTS) to patients and discuss next steps for technology development, research, and practice.

This guideline updates the state of the science on pain research, care, and education with a particular focus on informing the Food and Drug Administration's (FDA's) development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

This report describes changes in drug overdose death rates from 2019 to 2020, stratified by sex, age group, and race and ethnicity. In addition, it examines differences in circumstances surrounding drug overdose, and assesses differences in overdose death rates by county-level income inequality and availability of mental health treatment providers and providers of medications for opioid use disorder.